MY172886A - Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism - Google Patents

Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism

Info

Publication number
MY172886A
MY172886A MYPI2014003594A MYPI2014003594A MY172886A MY 172886 A MY172886 A MY 172886A MY PI2014003594 A MYPI2014003594 A MY PI2014003594A MY PI2014003594 A MYPI2014003594 A MY PI2014003594A MY 172886 A MY172886 A MY 172886A
Authority
MY
Malaysia
Prior art keywords
methylene
secondary hyperparathyroidism
dihydroxyvitamin
treat secondary
treat
Prior art date
Application number
MYPI2014003594A
Other languages
English (en)
Inventor
Hector F Deluca
Lori A Plum
Julia B Zella
Wendy Bedale
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY172886(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of MY172886A publication Critical patent/MY172886A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2014003594A 2012-06-29 2013-03-14 Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism MY172886A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
MY172886A true MY172886A (en) 2019-12-13

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014003594A MY172886A (en) 2012-06-29 2013-03-14 Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism

Country Status (19)

Country Link
US (4) US9205096B2 (enExample)
EP (1) EP2866811A1 (enExample)
JP (1) JP2015522015A (enExample)
KR (1) KR20150030673A (enExample)
CN (1) CN104394871A (enExample)
AU (1) AU2013281217B2 (enExample)
BR (1) BR112014032847A2 (enExample)
CA (1) CA2877680C (enExample)
CL (1) CL2014003565A1 (enExample)
CO (1) CO7240358A2 (enExample)
HK (1) HK1206600A1 (enExample)
IL (1) IL236184A0 (enExample)
MX (1) MX2015000076A (enExample)
MY (1) MY172886A (enExample)
NZ (1) NZ703347A (enExample)
RU (1) RU2666995C2 (enExample)
SG (1) SG11201408731WA (enExample)
WO (1) WO2014003849A1 (enExample)
ZA (1) ZA201500119B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201408731WA (en) * 2012-06-29 2015-01-29 Wisconsin Alumni Res Found USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D<sb>3</sb> TO TREAT SECONDARY HYPERPARATHYROIDISM
HUE039618T2 (hu) 2013-09-27 2019-01-28 Codexis Inc Enzimvariánsok automatizált szûrése
EP3049979B1 (en) * 2013-09-27 2020-01-01 Codexis, Inc. Structure based predictive modeling
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
WO2018044468A1 (en) 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
CA2404335C (en) 2000-03-27 2009-01-06 Wisconsin Alumni Research Foundation Vitamin d compounds used to stabilize kidney transplants
CN1217664C (zh) 2000-07-14 2005-09-07 威斯康星校友研究基金会 2－亚甲基－19－去甲－20(S)－1α，25－二羟维生素D3增加骨强度的用途
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
JP2007505882A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク 脆弱、筋損傷又はサルコペニアの治療のための２−アルキリデン−１９−ノル−ビタミンｄ誘導体
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
AU2006213727B2 (en) 2005-02-11 2011-08-18 Wisconsin Alumni Research Foundation 2-methylene-19-nor- (20S-24S) - 1alpha, 25-dihydroxyvitamin-D2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US20110034426A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of Preventing Renal Disease and Treating Symptoms Thereof
AU2011232633B2 (en) 2010-03-23 2014-05-29 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22- dimethyl-1alpha,25-hydroxyvitamin D3
SG11201408731WA (en) * 2012-06-29 2015-01-29 Wisconsin Alumni Res Found USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D<sb>3</sb> TO TREAT SECONDARY HYPERPARATHYROIDISM

Also Published As

Publication number Publication date
US9205096B2 (en) 2015-12-08
CA2877680A1 (en) 2014-01-03
US20160136184A1 (en) 2016-05-19
BR112014032847A2 (pt) 2017-06-27
AU2013281217A1 (en) 2015-01-22
US20140187522A1 (en) 2014-07-03
MX2015000076A (es) 2015-04-10
AU2013281217B2 (en) 2017-03-02
US10046000B2 (en) 2018-08-14
HK1206600A1 (en) 2016-01-15
CN104394871A (zh) 2015-03-04
CL2014003565A1 (es) 2015-08-28
EP2866811A1 (en) 2015-05-06
CA2877680C (en) 2017-08-29
US9034853B2 (en) 2015-05-19
WO2014003849A1 (en) 2014-01-03
SG11201408731WA (en) 2015-01-29
RU2015102831A (ru) 2016-08-20
IL236184A0 (en) 2015-01-29
KR20150030673A (ko) 2015-03-20
CO7240358A2 (es) 2015-04-17
ZA201500119B (en) 2017-11-29
US20170252360A1 (en) 2017-09-07
US9717744B2 (en) 2017-08-01
JP2015522015A (ja) 2015-08-03
US20140005152A1 (en) 2014-01-02
NZ703347A (en) 2016-05-27
RU2666995C2 (ru) 2018-09-13

Similar Documents

Publication Publication Date Title
MX2015000076A (es) Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.
PT3210430T (pt) Proibição de indicações de falha para falha de grupo de células secundárias
PH12016502167A1 (en) Hdl theraphy markers
IL247625B (en) Sewage treatment with primary treatment and - mbr (membrane bioreactor) or mabr-ifas (aerated membrane bioreactor - integrated fixed membrane activated by sludge)
SG11201404704UA (en) Database system using batch-oriented computation
PH12015500525A1 (en) Formulations of enzalutamide
IN2015DN00895A (enExample)
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
GT201400223A (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides
MX354598B (es) Uso de neuregulina para tratar lesion de nervio periferico.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
CL2017002304A1 (es) Métodos para tratar enfermedades
AR089320A1 (es) Cepa de lactobacillus mucosae
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
IL249994B (en) A power station with a fuel system for emergency use
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
BR112012024704A8 (pt) uso terapêutico de tetratiomolibdato.
IN2014KN01772A (enExample)
MX2013012083A (es) Biomarcadores para el tratamiento de mieloma multiple.
EP3240549A4 (en) Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
TR201818988T4 (tr) Multipl skleroz semptomlarını hafifletmeye yönelik apoaequorin içeren bileşimlere dayalı yöntemler.
MY164592A (en) Method for emulsion treatment
UA105605C2 (uk) Застосування штаму реліктових бактерій bacillus sp. f як радіаційнозахисного засобу